Clinical Trial

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 5, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live birth rate, EFS and OS.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-24.
Status change: Not Yet Recruiting → Recruiting 2024-11-01
Trial Details
NCT Number NCT06289062
Lead Sponsor Tongji Hospital
Collaborators: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Women's Hospital School Of Medicine Zhejiang University, Third Military Medical University, Beijing Friendship Hospital, Sichuan Cancer Hospital and Research Institute, Tianjin Medical University, West China Second University Hospital, Xiangya Hospital of Central South University, Qilu Hospital of Shandong University, Gansu Cancer Hospital, Zhejiang Cancer Hospital, Shengjing Hospital, Anhui Provincial Cancer Hospital
Conditions Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation
Enrollment 40 participants
Start Date 2024-05-08
Primary Completion 2025-12-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-05